Description

The Medical Industry segment has evolved significantly since the merger in 2013, where China Meheco consolidated assets from General Tianfang Pharmaceutical Group and China General Technology. This strategic move has amplified their capabilities within the pharmaceutical sector, allowing for an extensive production range that includes both chemical and biological raw materials, as well as various finished medicinal products.

China Meheco’s diverse offerings encompass 14 categories of pharmaceutical products, such as bulk pharmaceutical chemicals, antibiotics, tablets, injections, and capsules. Their medications effectively address a variety of health issues, including antibiotics for infections, treatments for cardio-cerebrovascular diseases, diabetes management, antiviral solutions, gastrointestinal relief, and non-steroidal anti-inflammatory drugs. With production bases strategically located in Hainan, Shanghai, Hubei, Henan, and Xinjiang, the company is well-positioned to focus on specialized and integrated fields, particularly in antibiotics, antiviral medications, specialty botanicals, and chronic disease management.

Specifications

Additional Information

China Meheco aims to enhance the differentiation and specialization within the pharmaceutical industry, focusing on internationalization and the development of characteristic fields. This commitment ensures that they remain at the forefront of pharmaceutical innovation and health solutions.